Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders

This article was originally published here

The company has closed a $45 million Series A financing led by SR One, with participation from Cormorant Asset Management, Quan Capital and WestRiver Group, to advance its

The post Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply